Clinical characteristics of healthy donors and multiple myeloma patients (immunoglobulins used in glycosylation analyses)
| Characteristic . | Healthy control subjects (n = 51) . | Without BD (n = 33) . | With BD (n = 43) . |
|---|---|---|---|
| Age (median), y | 60 | 64 | 65 |
| Sex (male) | 27 (52.9%) | 16 (48.5%) | 29 (67.4%) |
| Female | 24 | 17 | 14 |
| Untreated | NA | 31 | 36 |
| ISS 1 | NA | 10 | 10 |
| ISS 2 | NA | 6 | 13 |
| ISS 3 | NA | 4 | 9 |
| Unknown | NA | 13 | 11 |
| HB, g/L | 14.4 (12-17.5) | 11.1 (8.2-17.4) | 10.7 (7.3-14) |
| WBC (/L) | 6.8 (3.5-12.6) | 5.3 (2.2-8.2) | 6.3 (2.3-19) |
| TRC (/L) | 237 (137-377) | 229 (80-406) | 247 (26-607) |
| M component, g/L | NA | 40.0 (0-98.8) | 34.5 (1.4-105) |
| % PC | NA | 24 (5-70) | 33 (0-95) |
| Light chain κ | NA | 19* | 34* |
| Characteristic . | Healthy control subjects (n = 51) . | Without BD (n = 33) . | With BD (n = 43) . |
|---|---|---|---|
| Age (median), y | 60 | 64 | 65 |
| Sex (male) | 27 (52.9%) | 16 (48.5%) | 29 (67.4%) |
| Female | 24 | 17 | 14 |
| Untreated | NA | 31 | 36 |
| ISS 1 | NA | 10 | 10 |
| ISS 2 | NA | 6 | 13 |
| ISS 3 | NA | 4 | 9 |
| Unknown | NA | 13 | 11 |
| HB, g/L | 14.4 (12-17.5) | 11.1 (8.2-17.4) | 10.7 (7.3-14) |
| WBC (/L) | 6.8 (3.5-12.6) | 5.3 (2.2-8.2) | 6.3 (2.3-19) |
| TRC (/L) | 237 (137-377) | 229 (80-406) | 247 (26-607) |
| M component, g/L | NA | 40.0 (0-98.8) | 34.5 (1.4-105) |
| % PC | NA | 24 (5-70) | 33 (0-95) |
| Light chain κ | NA | 19* | 34* |
ISS, International Staging System; HB, hemoglobin; NA, not analyzed; PC, plasma cells; TRC, number of thrombocytes; WBC, white blood cells. NA
Seven unknown.